Minocycline for Bipolar Depression
Completed · Phase 4
Conditions studied: Bipolar Depression
In brief
The purpose of this study is to evaluate minocycline as a potential treatment for bipolar depression when added to a mood-stabilizing medication. Minocycline is an antibiotic that is approved for the treatment of infections and acne. Participation in this research study is expected to last 8 weeks, and includes five outpatient visits.
Key facts
- Study ID
- NCT01514422
- Run by
- Icahn School of Medicine at Mount Sinai
- People needed
- 20
- Starts
- 2011-05-01
- Expected to finish
- 2013-08-01
- Last updated by the study team
- 2017-01-30
Who can join
Age: 18 and older, up to 68. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Meets DSM-IV criteria for Bipolar I Disorder or Bipolar II disorder, depressed phase
- A baseline score of at least 18 on the Montgomery-Asberg Depression Rating Scale (MADRS)
- Participants on mood stabilizer medication for at least two weeks prior to starting the study, and must remain on the treatment during the study
- Able to understand English
You may not qualify if…
- DSM-IV diagnosis of Bipolar NOS, Cyclothymia, or Schizoaffective Bipolar type
- Pregnant women or women of child bearing potential who are not using a medically accepted means of contraception (defined as oral contraceptive pill or implant, condom, diaphragm, spermicide, IUD, s/p tubal ligation, partner with vasectomy)
- Serious suicide or homicide risk
- Unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease
- Clinical or laboratory evidence of hypothyroidism; if maintained on thyroid medication must be euthyroid for at least 1 month before visit 1
- Drug/alcohol dependence within past 30 days, or current substance use disorder that requires detoxification
- Current use of minocycline or history of anaphylactic reaction or intolerance to minocycline
- Primary clinical diagnosis of antisocial or borderline personality disorder
- Patients with metallic foreign bodies or claustrophobia will be excluded from the MRS component
Where it is running
- Icahn School of Medicine at Mount Sinai — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.